Analysts Swing to Diverse Views for ACADIA Pharmaceuticals Inc. (ACAD), Puma Biotechnology, Inc. (PBYI)

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) opened at $31.18, and ended -3.43% lower at $30.11. Nearly 0.85 million shares were traded by the close, lower than its average daily volume of 1.56 million shares.

ACADIA Pharmaceuticals Inc. (ACAD) Analyst Opinion

ACADIA Pharmaceuticals Inc. has a consensus outperform rating from 10 Wall Street analysts, and the number of shares currently sold short amount to at least 7.66% of shares outstanding. The stock spiked 3.76% last month and is up 4.4 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover ACAD having a buy-equivalent rating. Analysts have placed a $49.78 price target on ACADIA Pharmaceuticals Inc., suggesting a 65.33% gain from recent close. It’s currently trading about -26.92% below its 52-week high.

ACADIA Pharmaceuticals Inc. Earnings Surprise

ACADIA Pharmaceuticals Inc. (ACAD) surprised the stock market in its last reported earnings when it earned -$0.53 a piece versus the consensus-estimated -$0.62. Its revenue totaled $32.03 million up 5.09% from the previous quarter.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Intraday View

This stock (ACAD) is ahead of its 52-week low with 20.15%. Its last month’s stock price volatility remained 3.24% which for the week stands at 3.9%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.76% and stays -2.05% away from its 50 days moving average. Over the last five days, shares have managed 4.73% gains and now is down -4.99% since hitting its 200-day moving average of $31.87. ACADIA Pharmaceuticals Inc. (ACAD) has made its way to a 12-month gain of 4.58%.

Turning to Puma Biotechnology, Inc. (NASDAQ:PBYI), its shares were trading at $98.85 a retreat of $-0.95, on the trading floor. The stock, after opening at $100.55, touched a high of $100.55 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Puma Biotechnology, Inc. has 4 buy ratings, 1 holds and 0 sells even after the stock tumbled -27.79% from its high of $136.90 to a $3.71 billion market value through last close.

Puma Biotechnology, Inc. (PBYI) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.67 to 1.67 during a month. Analysts set a 12-month price target of $133.33 a share. The target implies a 34.88% spike from where the shares are currently trading. Also, the current price highlights a discount of 65.91% to analysts’ high consensus price target.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Intraday Trading

The counter witnessed a trading volume of 0.53 million shares versus an average volume of 0.75 million shares during last trading session. Its last month’s stock price volatility remained 2.78% which for the week approaches 5.14%. The lowest price the stock reached in the last trading day was $98.6 and compares with the $28.35 52-week low. The stock recovered 248.68% since its low point and has performed 221.99% year-to-date.

SHARE
Previous articleAnalyst Opinion On How To Bet On Stage Stores, Inc. (SSI), OncoSec Medical Incorporated (ONCS)
Next articleVaried Analyst Comments On Corbus Pharmaceuticals Holdings, Inc. (CRBP), Bellicum Pharmaceuticals, Inc. (BLCM)